📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Sai Life Sciences Partners with Mabtech to Launch Immunology Research Hub in Boston
Sai Life Sciences has announced a strategic collaboration with Swedish firm Mabtech to establish its Boston laboratory as a US execution and demonstration hub for the EYRA platform. This partnership enables Sai to offer advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, to global biopharma clients. The EYRA platform allows for the simultaneous detection of dozens of analytes in a single run, significantly enhancing Sai's discovery and translational research capabilities. This move strengthens the company's competitive position in high-growth sectors like immuno-oncology, vaccines, and cellular therapy.
Key Highlights
Sai’s Boston site becomes a co-marketed US execution hub for the Mabtech EYRA platform
Joint delivery of advanced immunology services targeting immuno-oncology and cellular therapy
EYRA platform enables simultaneous detection of dozens of analytes with minimal hands-on time
Strategic expansion of US discovery operations to accelerate biopharma development timelines
💼 Action for Investors
Investors should monitor the impact of this high-tech service expansion on Sai's US revenue growth and client acquisition. This collaboration enhances the company's value proposition in the specialized CRDMO market.
Sai Life Sciences Schedules Q3FY26 Earnings Conference Call for February 6, 2026
Sai Life Sciences Limited has announced its earnings conference call to discuss the un-audited financial results for the third quarter and nine months ended December 31, 2025. The call is scheduled for Friday, February 6, 2026, at 4:00 PM IST. Senior management, including MD & CEO Krishna Kanumuri and CFO Siva Chittor, will participate in the discussion and subsequent Q&A session. This event is a standard procedure for the company to provide transparency on its financial performance to the investor community.
Key Highlights
Earnings conference call scheduled for February 6, 2026, at 4:00 PM IST
Discussion will cover un-audited financial results for Q3 and 9M ended December 31, 2025
Management representation includes MD & CEO Krishna Kanumuri and CFO Siva Chittor
International toll-free dial-in options available for USA, UK, Singapore, and Hong Kong
💼 Action for Investors
Investors should track the financial results release on February 6 and listen to the management commentary for updates on the CRDMO project pipeline and margin outlook.